ArticleCureus2025
Steroid-Dependent Nephrotic Syndrome With Remission After Rituximab Implementation in a 14-Year-Old Boy: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steroid-dependent nephrotic syndrome (SDNS) in children poses significant therapeutic challenges due to frequent relapses and the risks linked to prolonged immunosuppressive treatment. We present a case of a 14-year-old boy diagnosed with steroid-sensitive nephrotic syndrome onset at three years old who progressed to steroid dependence with multiple relapses despite the therapy with calcineurin inhibitors and mycophenolate mofetil. The patient developed complications including growth retardation, Cushingoid features, and persistent hypertension. Renal biopsy confirmed focal segmental glomerulosclerosis (FSGS), which is a histological variant associated with poor treatment response. After limited success with conventional therapies administered from November 2013 to December 2024, rituximab was initiated, resulting in sustained remission and enabling complete withdrawal of immunosuppressive agents. Post-rituximab, the patient also received growth hormone therapy, which contributed to improved growth and overall clinical condition. This case highlights the complexity of managing SDNS with FSGS and supports rituximab's role in refractory cases, while underscoring the importance of monitoring for adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.